Company news
Exelixis, Inc. news in 2024
Exelixis, Inc.'s news releases, calls and decks from 2024, newest first.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
November 26, 2024
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
November 25, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 6, 2024
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
October 28, 2024
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 14, 2024
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
October 14, 2024
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
October 13, 2024
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
September 15, 2024
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
September 14, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
August 27, 2024
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 5, 2024
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 5, 2024
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 22, 2024
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 27, 2024
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 19, 2024
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 29, 2024
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 15, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 26, 2024
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 5, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
January 31, 2024
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
January 24, 2024
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 22, 2024
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 17, 2024
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
January 6, 2024
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
January 1, 2024